Yellowstone Biosciences, a pioneer of soluble bispecific T-cell receptor -based therapies for human leukocyte antigen Class II targets in oncology, launches to unlock a new class of therapeutically targetable, frequently expressed antigens with potential to significantly transform patient lives.
